What does the FDA's new at-home starting dose approval for Leqembi mean?

The FDA has authorized patients with Alzheimer’s to begin Leqembi therapy at home using a subcutaneous formulation instead of clinic IV infusions. This change provides comparable efficacy to the IV version, reduces procedural costs, and may expand early access, though safety monitoring for ARIA remains a key concern.